Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | FBP1 | P09467 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29963954 | 1.00 | TDP1 (0.52) | TDP1LMNAFBP1MGLLTSHR | |
| SCHEMBL20424323 | 1.00 | TDP1 (0.52) | TDP1LMNAFBP1MGLLTSHR | |
| SCHEMBL20441170 | 0.87 | TDP1 (0.41) | TDP1LMNAFBP1MGLLKDM4E | |
| SCHEMBL28893883 | 0.87 | TDP1 (0.41) | TDP1LMNAFBP1MGLLKDM4E | |
| SCHEMBL28893979 | 0.87 | TDP1 (0.41) | TDP1LMNAFBP1MGLLKDM4E | |
| SCHEMBL24351804 | 0.86 | TDP1 (0.56) | TDP1LMNAATMPLA2G4ASMN1; SMN2 | |
| SCHEMBL20424336 | 0.85 | TDP1 (0.67) | TDP1LMNAFBP1MGLLTSHR | |
| SCHEMBL20424334 | 0.85 | TDP1 (0.67) | TDP1LMNAFBP1MGLLTSHR | |
| SCHEMBL20424326 | 0.85 | TDP1 (0.71) | TDP1LMNAKMT2A | |
| SCHEMBL20424893 | 0.85 | TDP1 (0.71) | TDP1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710181-A | Compounds for reducing perception of malodour and uses thereof | 凯姆克姆公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20220378675-A1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | CHEMCOM S.A. (BE) | 2022-12-01 | — | — | US | disclosed |
| CN-110494413-B | Compounds for reducing perception of malodour and uses thereof | 凯姆克姆公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4059917-A2 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | ChemCom S.A. (BE) | 2022-09-21 | — | — | EP | disclosed |
| US-11382848-B2 | Compounds reducing malodour perception and the use thereof | CHEMCOM S.A. (BE) | 2022-07-12 | — | — | US | disclosed |
| US-11382848-B2 | Compounds reducing malodour perception and the use thereof | CHEMCOM S.A. (BE) | 2022-07-12 | — | — | US | disclosed |
| EP-3573944-B1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | CHEMCOM SA (BE) | 2022-03-02 | — | — | EP | disclosed |
| EP-3573944-B1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | CHEMCOM SA (BE) | 2022-03-02 | — | — | EP | disclosed |
| WO-2018138369-A1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | CHEMCOM S.A. (BE) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018138369-A1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | CHEMCOM S.A. (BE) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382848-B2 | Compounds reducing malodour perception and the use thereof | OR51E2, OR10J3, SRD5A1 | TDP1 4689/4885LMNA 4749/4885FBP1 1760/4885 |
| US-20220378675-A1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | OR51E2, OR10J3, SRD5A1 | TDP1 4689/4885LMNA 4749/4885FBP1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.